CROSSTREE

PINNACLE CLINICAL RESEARCH, A PORTFOLIO COMPANY OF LONGUEVUE CAPITAL, ACQUIRES KERWIN MEDICAL CENTER



Pinnacle Clinical Research, a Portfolio Company of LongueVue Capital, Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network and Trial Execution Capabilities

Recruiting and retaining patients for clinical trials presents a recurring challenge. Several factors contribute to the scarcity of participants, including geographical location and awareness of the trial. Particularly in Central Nervous System (CNS) trials, the intricate nature of these disorders often dissuades potential candidates.

Kerwin Medical Center ("KMC"), located in Dallas, TX, is committed to collaborating with the local community to address CNS diseases, with a focus in Alzheimer's Disease. Founded by Dr. Kerwin, the center prioritizes enhancing access to care in this field. With over two decades of experience in Alzheimer's and dementia research, Dr. Kerwin has established the facility as a reputable center, facilitating community involvement in clinical trials. This reputation and strict focus on CNS made KMC the ideal partner for Pinnacle Clinical Research ("Pinnacle"). With a separate focus in Metabolic Dysfunction-Associated

"Crosstree's proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today." Steatohepatitis (MASH), Pinnacle aims to expand its partnerships in CNS research, with a particular interest in Alzheimer's Disease. Through this new collaboration, Pinnacle will enhance its capability to identify eligible patients for these trials and expand its overall site network. This partnership also increases Pinnacle's geographic reach, bringing the total number of sites across the U.S. to 12. Additionally, the acquisition of KMC extends Pinnacle's therapeutic expertise into CNS indications, with a particular focus on Alzheimer's Disease.

Crosstree leveraged its extensive clinical research

site experience to assist Pinnacle in canvasing and evaluating potential partners in the market. Utilizing that same background, Crosstree connected current market trends to Pinnacle's capabilities to then create a compelling narrative to propose to potential partners, and ultimately identified Kerwin as the ideal partner to assist Pinnacle in reaching their growth objectives.



JASON LAYTON Managing Director jason.layton@crosstreecapital.com 813-578-7109

CROSSTREE

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

Deep analytics of capabilities and gaps Systemized tactical strategies and a road map to success

Engaged experts in market analysis, financials, and premium valuations

Targeted and qualified prospects

Up-to-date industry trend analysis and forecasting

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.



About Kerwin Medical Center

Kerwin Medical Center, based in Dallas, TX, is a top clinical research network with expertise in CNS studies, especially Alzheimer's Disease. KMC has one site in Dallas and is currently opening another in South Dallas. Founded in 2019 by Dr. Diana Kerwin, a leading expert with over 20 years of experience, KMC excels in phase I-III trials and NIH-funded studies. Dr. Kerwin, Board Certified in Internal Medicine and Geriatrics, is an Adjunct Assistant Professor at the University of Texas Southwestern Medical Center.

About Pinnacle Clinical Research

Pinnacle Clinical Research, founded by Dr. Stephen Harrison, specializes in complex therapeutic areas, offering high-quality patient care and superior enrollment timelines across twelve stand-alone sites. Led by a renowned physician team, Pinnacle focuses on pioneering treatments for complex diseases and serving underserved populations. The organization provides sponsors with a scaled network that ensures deep therapeutic expertise and superior clinical execution.

Pinnacle Clinical Research is a portfolio company of LongueVue Capital.



Other Recent Pharma Services Transactions:



